title: [Successful Treatment of Non-Small Cell Lung Cancer with Afatinib after Gefitinib-Induced Hepatotoxicity].
abstract: A 71-year-old man was referred to our hospital for treatment of non-small-cell lung cancer (adenocarcinoma of the lungs, with multiple bone metastases, cT1bN0M1b, harboring an EGFR mutation [exon 19 deletion]). Gefitinib was administered as daily oral doses of 250 mg. After 18 days, gefitinib was discontinued because of hepatotoxicity (Grade 3). Forty days later, afatinib was administered as daily oral doses of 40 mg. Within 1 year, the primary tumor and bone metastases achieved a partial response without hepatotoxicity. We suggest that afatinib is an effective and well-tolerated treatment option for patients with hepatotoxicity under gefitinib treatment.
authors.affiliation: Dept. of Pharmacy, Japanese Red Cross Society Suwa Hospital.
authors.forename: Aya
authors.initials: A
authors.lastname: Imai
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Hachiya
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ikuyama
authors.forename: Kei
authors.initials: K
authors.lastname: Sonehara
authors.forename: Aiko
authors.initials: A
authors.lastname: Fujimori
authors.forename: Hiroko
authors.initials: H
authors.lastname: Shiba
authors.forename: Osamu
authors.initials: O
authors.lastname: Atobe
mesh_terms: D000077716:Afatinib; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury; D000077156:Gefitinib; D006801:Humans; D008107:Liver Diseases; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077716:Afatinib; D000077156:Gefitinib